GoodRx Holdings Financial Statements (GDRX)
|
|
|
|
Report date
|
|
|
31.12.2022 |
01.03.2023 |
29.02.2024 |
27.02.2025 |
25.02.2026 |
|
06.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
766.6 |
766.6 |
750.3 |
792.3 |
796.9 |
|
787.9 |
|
Operating Income, bln rub |
|
|
1.74 |
1.74 |
-27.0 |
65.8 |
87.5 |
|
79.0 |
|
EBITDA, bln rub |
? |
|
65.2 |
65.2 |
108.8 |
153.9 |
184.4 |
|
175.2 |
|
Net profit, bln rub |
? |
|
-32.8 |
-32.8 |
-8.87 |
16.4 |
30.4 |
|
29.5 |
|
|
OCF, bln rub |
? |
|
146.8 |
146.8 |
138.3 |
183.9 |
167.9 |
|
170.3 |
|
CAPEX, bln rub |
? |
|
55.2 |
55.2 |
55.8 |
70.3 |
3.52 |
|
38.7 |
|
FCF, bln rub |
? |
|
91.6 |
91.6 |
82.5 |
113.5 |
164.4 |
|
131.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
699.7 |
699.7 |
710.3 |
678.3 |
651.8 |
|
624.7 |
|
Cost of production, bln rub |
|
|
65.1 |
65.1 |
66.9 |
48.2 |
57.6 |
|
84.1 |
|
R&D, bln rub |
|
|
143.1 |
143.1 |
135.8 |
123.7 |
121.0 |
|
120.1 |
|
Interest expenses, bln rub |
|
|
34.2 |
34.2 |
56.7 |
52.9 |
42.6 |
|
39.4 |
|
|
Assets, bln rub |
|
|
1 605 |
1 605 |
1 589 |
1 388 |
1 404 |
|
2 021 |
|
Net Assets, bln rub |
? |
|
814.8 |
814.8 |
762.0 |
724.7 |
616.3 |
|
622.0 |
|
Debt, bln rub |
|
|
65.2 |
717.0 |
711.1 |
543.4 |
59.5 |
|
58.9 |
|
Cash, bln rub |
|
|
757.2 |
757.2 |
672.3 |
448.3 |
261.8 |
|
235.7 |
|
Net debt, bln rub |
|
|
-691.9 |
-40.1 |
38.8 |
95.0 |
-202.3 |
|
-176.8 |
|
|
Ordinary share price, rub |
|
|
4.66 |
4.66 |
6.70 |
4.65 |
2.71 |
|
5.29 |
|
Number of ordinary shares, mln |
|
|
412.9 |
412.9 |
410.3 |
385.7 |
356.3 |
|
340.5 |
|
|
Market cap, bln rub |
|
|
1 924 |
1 924 |
2 749 |
1 794 |
966 |
|
1 801 |
|
EV, bln rub |
? |
|
1 232 |
1 884 |
2 788 |
1 889 |
763 |
|
1 625 |
|
Book value, bln rub |
|
|
283 |
213 |
195 |
137 |
122 |
|
130 |
|
|
EPS, rub |
? |
|
-0.08 |
-0.08 |
-0.02 |
0.04 |
0.09 |
|
0.09 |
|
FCF/share, rub |
|
|
0.22 |
0.22 |
0.20 |
0.29 |
0.46 |
|
0.39 |
|
BV/share, rub |
|
|
0.69 |
0.52 |
0.47 |
0.36 |
0.34 |
|
0.38 |
|
|
EBITDA margin, % |
? |
|
8.50% |
8.50% |
14.5% |
19.4% |
23.1% |
|
22.2% |
|
Net margin, % |
? |
|
-4.28% |
-4.28% |
-1.18% |
2.07% |
3.82% |
|
3.74% |
|
FCF yield, % |
? |
|
4.76% |
4.76% |
3.00% |
6.33% |
17.0% |
|
7.31% |
|
ROE, % |
? |
|
-4.03% |
-4.03% |
-1.16% |
2.26% |
4.94% |
|
4.74% |
|
ROA, % |
? |
|
-2.05% |
-2.05% |
-0.56% |
1.18% |
2.17% |
|
1.46% |
|
|
P/E |
? |
|
-58.6 |
-58.6 |
-310.0 |
109.4 |
31.7 |
|
61.1 |
|
P/FCF |
|
|
21.0 |
21.0 |
33.3 |
15.8 |
5.87 |
|
13.7 |
|
P/S |
? |
|
2.51 |
2.51 |
3.66 |
2.26 |
1.21 |
|
2.29 |
|
P/BV |
? |
|
6.80 |
9.04 |
14.1 |
13.1 |
7.92 |
|
13.8 |
|
EV/EBITDA |
? |
|
18.9 |
28.9 |
25.6 |
12.3 |
4.14 |
|
9.27 |
|
Debt/EBITDA |
|
|
-10.6 |
-0.62 |
0.36 |
0.62 |
-1.10 |
|
-1.01 |
|
|
R&D/CAPEX, % |
|
|
259.2% |
259.2% |
243.6% |
175.9% |
3 437% |
|
310.3% |
|
|
CAPEX/Revenue, % |
|
|
7.20% |
7.20% |
7.43% |
8.88% |
0.44% |
|
4.91% |
|
| GoodRx Holdings shareholders |
